{"id":36069,"date":"2023-04-27T09:30:55","date_gmt":"2023-04-27T07:30:55","guid":{"rendered":"https:\/\/www.satt.fr\/la-success-story-du-mois-biomadvanced-diagnostics\/"},"modified":"2023-04-27T09:42:58","modified_gmt":"2023-04-27T07:42:58","slug":"biomadvanced-diagnostics","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/","title":{"rendered":"La Success Story du mois : BIOMADVANCED DIAGNOSTICS"},"content":{"rendered":"
\n
\n\t

#R\u00e9volutionner le monde des diagnostics m\u00e9dicaux !<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\"\"<\/div><\/div>
\n
\n\t

BioMAdvanced Diagnostics est un start-up sp\u00e9cialis\u00e9e dans le d\u00e9veloppement, la fabrication et la distribution de dispositifs m\u00e9dicaux in-vitro bas\u00e9s sur les biotechnologies. <\/strong><\/p>\n

Son ambition est de r\u00e9volutionner le domaine des biomarqueurs li\u00e9s au syst\u00e8me immunitaire et de permettre de tendre vers une m\u00e9decine personnalis\u00e9e en fournissant des outils sans pr\u00e9c\u00e9dents aux cliniciens. Une grande attention est accord\u00e9e \u00e0 la diminution des risques pour les patients gr\u00e2ce \u00e0 des solutions peu invasives qui permettront des r\u00e9ductions de co\u00fbts tr\u00e8s importantes pour les syst\u00e8mes de sant\u00e9.<\/p>\n

 <\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

L\u2019\u00e9quipe des 5 cofondateurs de BioMAdvanced Diagnostics est une \u00e9quipe mixte compos\u00e9e de chercheurs et de managers. Sophie Brouard<\/strong>, M\u00e9daille de l\u2019innovation du CNRS 2020, directrice de recherche CNRS au CR2TI et Richard Danger<\/strong>, chercheur au CR2TI sont les inventeurs principaux des brevets exploit\u00e9s. Jean-Michel Bouler<\/strong> est chercheur au CEISAM (Nantes Universit\u00e9). Fr\u00e9d\u00e9ric Pette<\/strong> et Nicolas Bouler<\/strong> sont les managers ex\u00e9cutifs. Fr\u00e9d\u00e9ric Pette, Pr\u00e9sident et CEO apporte son exp\u00e9rience de manager international exp\u00e9riment\u00e9 dans le domaine du dispositif m\u00e9dical.<\/p>\n

La start-up incub\u00e9e par Atlanpole<\/strong>, et accompagn\u00e9e par la SATT Ouest Valorisation<\/strong><\/a>, a re\u00e7u plusieurs prix comme le prix de la R\u00e9gion Pays de la Loire lors de Start West 2021 et la bourse French Tech Emergence de Bpifrance.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

La technologie<\/h2>\n<\/div>\n<\/div><\/div><\/div><\/div>
\n
\n\t

La technologie ainsi transf\u00e9r\u00e9e porte sur l\u2019utilisation et l\u2019exploitation de 3 brevets concernant le diagnostic des patients ayant subi une transplantation du rein et\/ou du poumon. La solution propos\u00e9e par BioMAdvanced permettra notamment de r\u00e9duire le nombre de biopsies r\u00e9nales, un acte invasif et couteux.<\/p>\n

La technologie est issue des travaux de recherche de Mme Sophie Brouard, M. Richard Danger et Mme Magali Giral, du laboratoire CR2TI UMR 1064, ainsi que M. Pierre-Joseph Royer et M. Magnan, du laboratoire UMR 1087 INSTITUT DU THORAX. Les tutelles du CR2TI UMR 1064 sont Nantes Universit\u00e9 et l\u2019INSERM. Les tutelles de UMR 1087 INSTITUT DU THORAX sont Nantes Universit\u00e9, l\u2019INSERM et le CNRS. Le CHU de Nantes est partenaire des deux laboratoires.<\/p>\n<\/div>\n<\/div><\/div><\/div>

\"\"<\/div><\/div><\/div>
\n
\n\t

BioMAdvanced Diagnostics l\u00e8ve 1,7 million d'euros<\/strong><\/p>\n

La lev\u00e9e de fonds permettra \u00e0 BioMAdvanced Diagnostics de finaliser le design des premiers produits et de d\u00e9marrer deux \u00e9tudes cliniques, une sur le rejet des greffes de rein et l\u2019autre sur le poumon. La validation du test de diagnostic du rein s\u2019appuiera sur une \u00e9tude effectu\u00e9e sur plus de 300 \u00e9chantillons de patients ayant subi une transplantation et issus d\u2019\u00e9tudes nationales et internationales men\u00e9es par le CHU de Nantes, avec la contribution notamment des h\u00f4pitaux universitaires de Barcelone et Oslo. Cette \u00e9tude d\u00e9bouchera sur l\u2019obtention du marquage CE pour une mise sur le march\u00e9 pr\u00e9vue en 2025.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
<\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t

\u00ab Cet accord de licence exclusive porte sur 3 brevets et concr\u00e9tise le travail d\u2019accompagnement conduit depuis plusieurs ann\u00e9es sur des innovations de rupture aux potentiels exceptionnels. R\u00e9compens\u00e9e par la fondation Grand Ouest en d\u00e9cembre 2021, nous nous r\u00e9jouissons de la reconnaissance port\u00e9e \u00e0 BioMAdvanced Diagnostics. Nous continuerons d\u2019\u00eatre \u00e0 ses c\u00f4t\u00e9s pour qu\u2019elle devienne une r\u00e9f\u00e9rence dans le domaine des biomarqueurs li\u00e9s au syst\u00e8me immunitaire.<\/em> \u00bb d\u00e9clare Cyrille Chapon, Directeur Transfert de Ouest Valorisation<\/strong>.<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
<\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t

\u00ab Les 3 brevets d\u00e9pos\u00e9s par notre \u00e9quipe de recherche ont \u00e9t\u00e9 r\u00e9dig\u00e9s en partenariat avec la SATT Ouest valorisation qui nous accompagne \u00e9galement dans les domaines de la transplantation et des maladies auto-immunes. Notre \u00e9quipe s\u2019est engag\u00e9e dans la soci\u00e9t\u00e9 d\u2019abord par le transfert de ses brevets, et par ailleurs, Richard Danger et moi-m\u00eame sommes \u00e9galement co-fondateurs de BioMAdvanced Diagnostics, et participons activement \u00e0 son fonctionnement, en tant que Pr\u00e9sidente du Conseil Scientifique International en ce qui me concerne, et Conseiller de strat\u00e9gie technologique pour richard Danger.<\/em> \u00bb souligne Sophie Brouard, Directrice Adjointe du CR2TI UMR 1064 et cofondatrice de la soci\u00e9t\u00e9 BioMAdvanced Diagnostics.<\/strong><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
<\/div>\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/strong><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t

\u00ab\u00a0Les greffes de rein sont en augmentation partout dans le monde et c\u2019est pour les greff\u00e9s du rein que nous allons d\u00e9velopper notre premier produit. Nos objectifs sont de commercialiser dans 12 pays d\u00e8s 2026 pour en faire b\u00e9n\u00e9ficier 70 \u00e0 80% des patients. Nous avons pr\u00e9vu un 2\u00e8me<\/sup> tour de table d\u00e8s 2024 pour finaliser les \u00e9tudes cliniques et pr\u00e9parer notre pr\u00e9sence commerciale dans ces 12 pays, et probablement, ouvrir une filiale aux Etats-Unis.<\/em>\u00a0\u00bb pr\u00e9cise Fr\u00e9d\u00e9ric Pette, co-fondateur et CEO de BioMAdvanced Diagnostics.<\/strong><\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

#R\u00e9volutionner le monde des diagnostics m\u00e9dicaux ! BioMAdvanced Diagnostics est un start-up sp\u00e9cialis\u00e9e dans le d\u00e9veloppement, la fabrication et la distribution de dispositifs m\u00e9dicaux in-vitro bas\u00e9s sur les biotechnologies. Son ambition est de r\u00e9volutionner le domaine des biomarqueurs li\u00e9s au syst\u00e8me immunitaire et de permettre de tendre vers une m\u00e9decine personnalis\u00e9e en fournissant des outils […]<\/p>\n","protected":false},"author":2,"featured_media":36066,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568],"tags":[],"class_list":["post-36069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en"],"acf":[],"yoast_head":"\nLa Success Story du mois : BIOMADVANCED DIAGNOSTICS - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"headline\":\"La Success Story du mois : BIOMADVANCED DIAGNOSTICS\",\"datePublished\":\"2023-04-27T07:30:55+00:00\",\"dateModified\":\"2023-04-27T07:42:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/\"},\"wordCount\":519,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png\",\"articleSection\":[\"News\",\"Success Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/\",\"url\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/\",\"name\":\"La Success Story du mois : BIOMADVANCED DIAGNOSTICS - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png\",\"datePublished\":\"2023-04-27T07:30:55+00:00\",\"dateModified\":\"2023-04-27T07:42:58+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png\",\"width\":1434,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La Success Story du mois : BIOMADVANCED DIAGNOSTICS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec\",\"name\":\"admin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La Success Story du mois : BIOMADVANCED DIAGNOSTICS - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/"},"author":{"name":"admin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"headline":"La Success Story du mois : BIOMADVANCED DIAGNOSTICS","datePublished":"2023-04-27T07:30:55+00:00","dateModified":"2023-04-27T07:42:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/"},"wordCount":519,"image":{"@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png","articleSection":["News","Success Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/","url":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/","name":"La Success Story du mois : BIOMADVANCED DIAGNOSTICS - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png","datePublished":"2023-04-27T07:30:55+00:00","dateModified":"2023-04-27T07:42:58+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2023\/04\/la-successstory-du-mois-3.png","width":1434,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/biomadvanced-diagnostics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La Success Story du mois : BIOMADVANCED DIAGNOSTICS"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d'Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/6f20a7d0bc03146f6e34a9f08d941fec","name":"admin","url":"https:\/\/www.satt.fr\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/36069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=36069"}],"version-history":[{"count":5,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/36069\/revisions"}],"predecessor-version":[{"id":36109,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/36069\/revisions\/36109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/36066"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=36069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=36069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=36069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}